Two neurotrophic factor gene therapies delivered via AAV2 vectors have provided either neurturin (AAV2-NRTN) or glial cell-line derived neurotrophic factor (AAV2-GDNF) to PD patients. Here, GDNF is linked to Parkinson disease.